Amphastar Pharmaceuticals's revenue for the
three
months ended in Dec. 2023 was $178.1 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $644.4 Mil.
Amphastar Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2023 was $3.36.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $12.15.
During the past 12 months, the average Revenue per Share Growth Rate of Amphastar Pharmaceuticals was 27.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Amphastar Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 19.50% per year. The lowest was -42.80% per year. And the median was 5.30% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amphastar Pharmaceuticals's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Revenue falls into.
Amphastar Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $644.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Amphastar Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMPH has been successfully added to your 